Summary & Overview
HCPCS J2356: Injection, tezepelumab-ekko, 1 mg
HCPCS Level II code J2356 identifies the injectable biologic tezepelumab-ekko, billed per 1 mg unit. This code is used when recording drug supply for tezepelumab-ekko, a monoclonal antibody therapy with applications in certain inflammatory and respiratory conditions. Nationally, accurate reporting of J2356 is important for clinical documentation, reimbursement, drug utilization monitoring, and budget planning for providers and payers.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of what J2356 represents, typical sites of service for administration, and the payer landscape that shapes coverage and billing practices. The publication covers billing benchmarks, common payer policies and coverage considerations, and the clinical context for tezepelumab-ekko use. It also highlights typical billing patterns and coding nuances relevant to hospital outpatient departments and physician offices.
This summary is intended for national audiences involved in medical billing, revenue cycle management, payer policy, and clinical program planning who need a clear, practical reference for HCPCS Level II code J2356.
Billing Code Overview
HCPCS Level II code J2356 represents an injection of tezepelumab-ekko, 1 mg. This code denotes the drug product and unit of measure used for administration of tezepelumab-ekko, an injectable biologic therapy.
Service Type: Drug administration (injectable biologic), billed per milligram
Typical Site of Service: Outpatient infusion/clinic setting or physician office
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient receiving J2356 (tezepelumab-ekko, 1 mg) is an adult or adolescent with severe uncontrolled asthma despite high-dose inhaled corticosteroids plus another controller and, often, previous biologic therapy. The clinical workflow begins with specialist evaluation in an outpatient allergy/immunology or pulmonology clinic. The patient presents with persistent symptoms (daily wheeze, frequent exacerbations, reduced lung function) and objective evidence of type 2 inflammation may be present but is not required for tezepelumab-ekko use.
After confirmation of eligibility and documented prior therapy failures, baseline assessments are obtained: spirometry, exacerbation history, current medications, and relevant labs. The drug is supplied as a prefilled syringe or single-use vial; the ordered dose is converted to milligrams and billed as units of J2356 (1 mg per unit). Administration is typically by subcutaneous injection in the clinic by a licensed nurse. Observation for immediate adverse reactions follows per facility protocol (commonly 15–30 minutes). Dosing occurs every 4 weeks after an initial loading schedule per product labeling. Documentation includes indication, dose in mg and units billed, lot number, route (subcutaneous), site, patient consent, and any observation findings.
Typical site of service is an outpatient infusion or injection clinic, physician office, or ambulatory care setting. Pharmacy dispensing and storage documentation is maintained per provider and payer rules. Billing often pairs J2356 with appropriate visit codes and, when applicable, injection administration CPT codes or facility revenue codes; clinical documentation supports medical necessity for severe asthma management.